

Monoclonal Anti-Zaire Ebola Virus Envelope Glycoprotein, Clone 6E9D2 (produced *in vitro*)

Catalog No. NR-49264

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor and Manufacturer:

Gerardo Kaplan, Ph.D., Senior Investigator, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA

Product Description:

Antibody Class: IgG1k

Mouse monoclonal antibody prepared against the envelope glycoprotein (GP) of Zaire ebolavirus (EBOV) was purified from clone 6E9D2 hybridoma supernatant by protein G affinity chromatography. The B cell hybridoma was generated by the fusion of mouse myeloma cells with splenocytes from mice that had been immunized intraperitoneally with purified recombinant ZEBOVGP-Fc, which consists of the extracellular domain of the Zaire EBOV GP fused to the human IgG1 Fc fragment.¹

Material Provided:

Each vial of NR-49264 contains approximately 100 µL of purified monoclonal antibody in PBS, pH 7.2. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-49264 was packaged aseptically in screw-capped plastic cryovials and is provided frozen on dry ice. NR-49264 should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-49264 is reported to be specific for the mucin region of the Zaire ebolavirus envelope glycoprotein and to function in immunocytochemistry, immunohistochemistry, immunoprecipitation and western blot assays.²

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Zaire Ebola Virus Envelope Glycoprotein, Clone 6E9D2 (produced *in vitro*), NR-49264.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and

Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Konduru, K., et al., “Ebola Virus Glycoprotein Fc Fusion Protein Confers Protection Against Lethal Challenge in Vaccinated Mice.” Vaccine 29 (2011): 2968-2977. PubMed: 21329775.
2. Kaplan, G., Personal Communication.

ATCC® is a trademark of the American Type Culture Collection.

